Download DNB 2015 Dec DERMATOLOGY VENEREOLOGY AND LEPROSY IV Question Paper

Download DNB (Diplomate of National Board) Under NBE 2015 Dec DERMATOLOGY VENEREOLOGY AND LEPROSY IV Previous Question Paper

FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
DECEMBER 2015
-1-
POSSESSION / USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.

DERMATOLOGY, VENEREOLOGY AND LEPROSY

PAPER ? IV
DVD/D/15/06/IV
Time : 3 hours
Max. Marks : 100

Important instructions:

? Attempt all questions in order.
? Each question carries 10 marks.
? Read the question carefully and answer to the point neatly and legibly.
? Do not leave any blank pages between two answers.
? Indicate the question number correctly for the answer in the margin space.
? Answer all the parts of a single question together.
? Start the answer to a question on a fresh page or leave adequate space between two answers.
? Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. a) ?Biosimilars?.
b) Discuss one of the biosimilars used frequently in
Dermatology.

6
4
2. a) What is ?off label? use of an agent in Dermatology?
b) Enumerate the conditions where azathioprine is used in
Dermatology.

7
3
3. Immune Reconstruction Syndrome:
a) Mechanism.
b) Clinical features.
c) Management.

4
3
3

4. Recent advances related to management of:
a) Hemangiomas.
b) Atopic dermatitis.


5
5
5. a) Current controversies on ?fairness? creams.
b) Anti-ageing procedures on face.
4
6

6. a) Role of Rituximab in Dermatology
b) Non-cultured melanocyte transfer in vitiligo.

5
5
7. a) Vitiligo Impact Scale-22.
b) Diagnostic clinical features of pentazocine induced ulcers.
6
4

8. a) Current scenario of leprosy eradication programme in India.
b) What is the current prevalence of leprosy:
(i) in the world (with year)
(ii) in India (with year)




8

1
1

P.T.O.


FirstRanker.com - FirstRanker's Choice
FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
DECEMBER 2015
-1-
POSSESSION / USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.

DERMATOLOGY, VENEREOLOGY AND LEPROSY

PAPER ? IV
DVD/D/15/06/IV
Time : 3 hours
Max. Marks : 100

Important instructions:

? Attempt all questions in order.
? Each question carries 10 marks.
? Read the question carefully and answer to the point neatly and legibly.
? Do not leave any blank pages between two answers.
? Indicate the question number correctly for the answer in the margin space.
? Answer all the parts of a single question together.
? Start the answer to a question on a fresh page or leave adequate space between two answers.
? Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. a) ?Biosimilars?.
b) Discuss one of the biosimilars used frequently in
Dermatology.

6
4
2. a) What is ?off label? use of an agent in Dermatology?
b) Enumerate the conditions where azathioprine is used in
Dermatology.

7
3
3. Immune Reconstruction Syndrome:
a) Mechanism.
b) Clinical features.
c) Management.

4
3
3

4. Recent advances related to management of:
a) Hemangiomas.
b) Atopic dermatitis.


5
5
5. a) Current controversies on ?fairness? creams.
b) Anti-ageing procedures on face.
4
6

6. a) Role of Rituximab in Dermatology
b) Non-cultured melanocyte transfer in vitiligo.

5
5
7. a) Vitiligo Impact Scale-22.
b) Diagnostic clinical features of pentazocine induced ulcers.
6
4

8. a) Current scenario of leprosy eradication programme in India.
b) What is the current prevalence of leprosy:
(i) in the world (with year)
(ii) in India (with year)




8

1
1

P.T.O.


FINAL EXAM NATIONAL BOARD OF EXAMINATIONS
DECEMBER 2015
-2-
POSSESSION / USE OF CELL PHONES OR ANY SUCH ELECTRONIC GADGETS IS NOT PERMITTED INSIDE THE
EXAMINATION HALL.

DERMATOLOGY, VENEREOLOGY AND LEPROSY

PAPER ? IV


9. a) Enumerate the newer anti-retroviral drugs. Discuss any two
of these drugs.
b) ATT in a patient with HIV.

6

4
10. a) Platelet-rich plasma.
b) Permanent fillers.
c) Camouflage in vitiligo.
4
3
3

**********************
FirstRanker.com - FirstRanker's Choice

This post was last modified on 29 April 2020